REVIEWPrevalence of Monoclonal Gammopathy of Undetermined Significance: A Systematic Review
Section snippets
Data Sources and Searches
This review was conducted from January 6, 2009, through January 15, 2010. A systematic literature search of PubMed was completed to identify all studies investigating the prevalence and incidence of MGUS. The following MeSH search headings were used: monoclonal gammopathy, benign and prevalence; monoclonal gammopathy, benign and incidence; paraproteinemia and prevalence; and paraproteinemia and incidence. Articles were limited to those written in English and published by January 2009.
Study Selection
Abstracts
RESULTS
Of the 14 studies pertaining to the epidemiology of MGUS (Table 3), 11 (79%) included prevalence measures (Table 4). Of these, 6 (55%) were population-based, 3 (27%) were studiesof hospital populations, and 2 (18%) were retrospective. The remaining 3 studies, 2 of which were retrospective, registry-based studies and one of which was a hospital series study, provided estimates of the incidence of MGUS (Table 5).
DISCUSSION
MGUS falls under an overarching group of plasma cell disorders known as monoclonal gammopathies (or paraproteinemias). This broad category of conditions includes MGUS, multiple myeloma, Waldenström macroglobulinemia, and primary amyloidosis.50 To date, this is the first systematic review of the descriptive epidemiology of MGUS.
The true frequency of MGUS can most accurately be determined through population-based studies that test persons in a geographically defined area during a specified
CONCLUSION
MGUS is one of the most common premalignant disorders in the general population. It is clear that epidemiological investigations will aid in the identification of groups at a high risk of MGUS and thus at a high risk of the subsequent development of multiple myeloma. Such insight will be beneficial for early screening and intervention in high-risk demographics. Future epidemiological investigations must standardize the criteria used for the diagnosis of MGUS, establish universal methods to
Acknowledgments
We extend our gratitude to Victoria A. Dickens, MA, Wael Salem, MPhil, and Fima Macheret, BS, for their thoughtful insight.
REFERENCES (50)
- et al.
Multiple myeloma
Blood
(2008) - et al.
Improved survival in multiple myeloma and the impact of novel therapies
Blood
(2008) - et al.
Disease associations with monoclonal gammopathy of undetermined significance: a population-based study of 17,398 patients
Mayo Clin Proc
(2009) - et al.
Long-term follow-up of 241 patients with monoclonal gammopathy of undetermined significance: the original Mayo Clinic series 25 years later
Mayo Clin Proc
(2004) - et al.
Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance
Blood
(2005) - et al.
Racial differences in the prevalence of monoclonal gammopathy in a community-based sample of the elderly
Am J Med
(1998) - et al.
Prevalence of monoclonal gammopathy of undetermined significance: study of 52,802 persons in Nagasaki City, Japan
Mayo Clin Proc
(2007) - et al.
Incidence of monoclonal proteins in a Minnesota community with a cluster of multiple myeloma
Blood
(1972) - et al.
Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States
Blood
(2006) - et al.
Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana
Mayo Clin Proc
(2007)
Monoclonal gammopathies of undetermined significance
Best Pract Res Clin Haematol
Oligoclonal immunoglobulins in patients with the acquired immunodeficiency syndrome
Clin Immunol ImmunoPathol
Pesticide exposure and risk of monoclonal gammopathy of undetermined significance in the Agricultural Health Study
Blood
Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance
Blood
Epidemiology of the plasma-cell disorders
Best Pract Res Clin Haematol
MGUS and smoldering multiple myeloma: update on pathogenesis, natural history, and management
Hematology Am Soc Hematol Educ Program
Multiple myeloma
N Engl J Med
A long-term study of prognosis in monoclonal gammopathy of undetermined significance
N Engl J Med
Pathogenesis and progression of monoclonal gammopathy of undetermined significance
Leukemia
Monoclonal gammopathy of undetermined significance
Br J Haematol
Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group
Br J Haematol
Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma
Leukemia
Prevalence of monoclonal gammopathy of undetermined significance
N Engl J Med
Occurrence of monoclonal components in general practice: clinical implications
Eur J Haematol
Incidence and evolution of monoclonal gammopathy of undetermined significance (MGUS) in Greece
Ann Hematol
Cited by (116)
An overview of multiple myeloma: A monoclonal plasma cell malignancy's diagnosis, management, and treatment modalities
2024, Saudi Journal of Biological SciencesVEXAS syndrome, a new kid on the block of auto-inflammatory diseases: A hematologist's point of view
2023, Best Practice and Research: Clinical RheumatologyPatient's perspectives of living with a precancerous condition: Monoclonal gammopathy of undetermined significance (MGUS)
2021, European Journal of Oncology NursingCitation Excerpt :The annual rate of progression to MM and related lymphoproliferative disorders such as Waldenström's macroglobulinemia, and lymphoma has been reported to be 1% (Kyle et al., 2002), meaning the vast majority of individuals diagnosed with MGUS will not progress to MM. MGUS is more common in males (Wadhera and Rajkumar, 2010), and individuals of black ethnicity (Landgren et al, 2006, 2007). Younger age at diagnosis has been reported among black individuals (median age of diagnosis: 66 vs 70 years old (white individuals) (Landgren et al., 2017).
This study was supported in part by grants CA107476 and CA62242 from the National Cancer Institute, Bethesda, MD.
An earlier version of this article appeared Online First.
This article is freely available on publication, because the authors have chosen the immediate access option.